Redeye is encouraged to learn that Faron has received positive FDA feedback and recommendations for the future development of lead candidate Bexmarilimab as a monotherapy in multiple solid tumors. We believe this is a great validation of Faron’s development plan for Bexmarilimab and the robust clinical data package generated through the MATINS trial.
LÄS MER